These epigenetic modifications suppress NLRP3 expression, inhibit the activation of the NLRP3- caspase-1- GSDMD pathway, and confer an anti-pyroptotic phenotype to lung cancer cells [197]. This evidence concerns the gene NLRP3 and lung carcinoma.